The Manufacturing Bottleneck
The COVID-19 pandemic exposed how manufacturing capacity, not just vaccine science, can become a critical bottleneck during global health emergencies, with wealthy nations securing the vast majority of early vaccine supply while lower-resource countries waited far longer for access, a disparity driven substantially by limited global manufacturing capacity and technology concentrated in relatively few locations and companies.
Advances Addressing the Bottleneck
In response, considerable investment and innovation has focused on more distributed, flexible, and scalable manufacturing approaches, including technology transfer initiatives that establish vaccine manufacturing capacity in more regions rather than concentrating it exclusively in traditional manufacturing hubs, and platform technologies like mRNA that can potentially be manufactured more rapidly and flexibly than some traditional vaccine production methods.
The Equity Implications
If these manufacturing innovations succeed at reducing cost and increasing distributed capacity, the implications extend beyond convenience to genuine improvements in global vaccine equity and pandemic preparedness, potentially preventing the stark access disparities that characterized early COVID vaccine distribution from recurring during future health emergencies. Facilities can source lab supplies and pharmacy supplies from our catalog.
